About BluMaiden

End-to-End Solutions from Microbiome-based AI Discovery Engines

Led by an experienced board and executive team, BluMaiden Biosciences is providing value add outputs for Pharma and Industry players across clinical trials and drug discovery.

Our Expert Network

The BluMaiden Biosciences science team is currently located both in Singapore and Europe. With the founding team located in Singapore, we are backed by a global and ever-expanding expert network through our science advisors, partners, and investors.

Embracing Diversity

Diverse and inclusive teams have a positive impact on our products and services, and help us better serve our partners, employees, and stakeholders from every background. We are constantly learning and iterating, whether through central programs, or work within our business teams, through programs that are local, regional, and global. BluMaiden Biosciences are aware that our current team composition does not fulfil our diversity goals. As an early company, securing expertise and moving the business plan forward fast are important drivers. We are actively recruiting for diverse candidates to fill many board and senior positions.

Board of Directors

Damien Keogh, Ph.D
Director

Dr. Keogh is the Chief Executive Officer and Founding Member of BluMaiden Biosciences. He has assembled the founding team and recruited a distinguished Board of Directors and Scientific Advisors. Dr. Damien Keogh is a data-driven and innovative scientist with a background in biotechnology, commercialization, and entrepreneurship. Following undergraduate studies in Biotechnology he obtained a PhD in Microbiology

Michael Tillman  
Chairman

Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry.

Terence A. Kelly, Ph.D
Director

Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.

Robert Meyer
Director

Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities.

Our Team

Rohan Williams, Ph.D
Chair of SAB, Computational Bio Expert

Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology

Damian O’Connell, Ph.D
Scientific Advisory Board, Member

Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.

Kim Lewis, Ph.D        Scientific Advisory Board, Member

Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts.

Nicholas Talley, Ph.D
Scientific Advisory Board, Member

Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.

Stephen Simpson, Ph.D
Scientific Advisory Board, Member

Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia

End-to-End Deep Domain Expertise

Highly Trained Team With Global Footprint Of Training And Experience

We Have Expertise Across:

Europe

Singapore

Australia

List Of Expertise Areas:

Our Vision And Mission

Unlocking the potential of human microbiome with deep tech

The answer to human health lies within our own body. The human microbiome has co-evolved with human populations through millennia and has developed powerful ways to regulate human health through secreted signaling molecules. This reservoir of microbiome-derived compounds, naturally found and working in our own bodies, offers a safer and more efficient way to improve health, but remains largely untapped. Backed by our investors, advisory boards and partners, the BluMaiden team is on a mission to uncover the intricate connection between microbiome signals and human health for the development of therapeutics, diagnostics, and digital health technologies.

Our Values

1. Pioneering Spirit

+ We venture beyond boundaries to tackle unmet needs in new ways

+ Dare to think differently to change the status quo

+ Innovative integrated platform technology and analytics streamlines the road to drug discovery.

2. Holistic Point of View

+ Big picture thinkers who invest in the outcomes

+ We’ve integrated data capture, analysis, and discovery for a seamless drug discovery process

+ Seek partnerships and effective co-creation with consumers and pharma companies

3. Uphold Excellence

+ Pursue a high level of intellectual and scientific rigor

+ Welcome obstacles and challenges as opportunities to improve and innovate

+ We invest in people, the foundation of an enduring company

4. Do Right

We own our actions

+ Act with conviction, compassion and empathy

+ Uphold a high ethical conduct in our research and process

+ Dedicated to the science and better outcomes for all

Code of Conduct

We strongly believe that compliance & ethics are essential to preserve and strengthen the trust of our patients, business partners, shareholders and communities. We ensure transparency in all aspects of our business operation, conduct ourselves at all times in accordance with our vision and values as outlined in our Code of Conduct, and hold ourselves accountable for meeting the expectations we place on ourselves.

Get In Touch

If you have a general question for us or want to explore a partnership opportunity, then please reach out to us here.

Get In Touch

If you have a general question for us or want to explore a partnership opportunity, then please reach out to us here.

Damien Keogh, Ph.D
Chief Executive Officer

Damien Keogh, Ph.D. has served as BluMaiden Biosciences Chief Executive Officer and Board of Directors Member since August 2020. Prior to co-founding the Company, Dr. Keogh was actively engaged in the Biotechnology sector with roles in venture capital as Entrepreneur-in-residence, spin-out and venture created biotechnology companies, and has earned an alumni of Johnson & Johnson Innovation JLABS. Dr. Keogh continues to support and engage with both start-up companies and entrepreneurs in their strategic positioning and development. During his academic career Dr. Keogh worked closely with Pharma leaders, clinician scientists, and academic research scientists to develop new methods and insights to metabolite biology, (poly)microbial-host interactions, and microbial biofilm dynamics.  His early research work was sponsored by the Pharmaceutical company Bristol Myers Squibb Ltd. with the aim of developing molecular tools to enhance drug purification with novel glycoselective bioaffinity tools. Dr. Keogh has many years of experience working with multidisciplinary scientific teams to develop insights and applications with state-of-the-art technologies. Dr. Keogh received his PhD (Molecular Microbiology) and his Bachelor of Science in Biotechnology at Dublin City University (Ireland).

Michael Tillmann
Chairman

Mr. Tillmann is a seasoned CEO, board member and entrepreneur with 30 years of experience in the pharmaceutical and diagnostics industry. Mr. Tillmann has a stellar 30-year track-record in the pharmaceutical and diagnostics industry. Having served Roche Diagnostics as its Asia Pacific and North America CEO with a seat in the Roche Global Executive Board, Mr. Tillmann has been running his own bio-tech incubator Amatar Group since 2010. In this role, he also founded Vela Diagnostics Ltd, which was acquired by the Luye Lifescience Group in 2020. Mr. Tillmann sits in multiple supervisory & advisory boards. Additionally, he supports companies in their strategic positioning and M&A activities, where he advised in his latest project AmpTec GmbH, which was acquired by Merck KGaA, Germany.

Terence A. Kelly, Ph. D
Director

Dr. Kelly is a scientific leader with both Pharma and Biotech experience and a track record of delivering high quality compounds into advanced clinical studies. He is expert in chemistry, disease biology and the enabling technologies needed for innovative and efficient drug discovery from lead identification through clinical development.

Between 1990 and 2009, Terry served in various scientific and executive positions at Boehringer Ingelheim, where after a successful early career developing LFA-1 antagonists, he led its US-based medicinal chemistry department.  From 2010 – 2016 he was the CEO and CSO of CoMentis, Inc, a venture-backed biotech focusing on treating cognitive disorders.  He is a founder of Kelly Pharma Research Consulting, LLC and has served as a director of Cardax, Inc. since June 2014. Terry is currently the President and CEO of Perception Neuroscience, a clinical stage biotech company developing small molecule therapeutics for mental health disorders.

Terry holds a B.S. degree in Chemistry at Rensselaer Polytechnic Institute and a Ph.D. degree in Chemistry at the University of Texas at Austin. He completed postdoctoral work in natural products synthesis at Yale University (1988-1990) and holds an MBA from New York University. Dr. Kelly is the co-author of over 25 scientific publications and served on the College of Natural Sciences Advisory Council for the University of Texas.

Robert Meyer
Director

Robert is the founder and Managing Partner of Angsana Investments Pte Ltd, a private venture firm that is focussed on direct investments in early-stage opportunities. Robert is also the CEO of Caber Partners Pte Ltd, an Alternative Asset Manager licensed by the Monetary Authority of Singapore (MAS) as Fund Manager and Exempt Financial Advisor. In June 2021, Caber launched the Angsana Natural Rubber Opportunities Fund I (“ANRO”), a macro hedge fund that positions in rubber futures and derivatives. Prior to launching Angsana, Robert co-founded SGX-listed Halcyon Agri Corporation Limited and served as its CEO from January 2013 to June 2020. During his tenure, Halcyon Agri executed a buy-and-build roll-up strategy to create the world’s largest rubber franchise. In 2016, Halcyon Agri acquired the natural rubber business of Chinese state-owned Sinochem International Limited in a landmark transaction that valued the enlarged group at USD800m. At Halcyon Agri, Robert also initiated the launch of HeveaConnect, the world’s first digital marketplace for sustainable natural rubber, in partnership with Itochu Corporation and DBS Bank Limited and, most recently, SGX. Robert has a keen interest in geopolitics and served on Singapore’s Economic Strategies Committee (ESC) in 2010. Presently, Robert is a member of the National University of Singapore Health International Council (NIC).

Rohan Williams, Ph.D
Scientific Co-Founder Computational Biology and Chair of SAB

Rohan Williams is a computational biologist, specialising in bioinformatics and systems biology of microbiomes and microbial ecology. Following undergraduate studies in Physics he obtained a PhD in Medicine at the University of New South Wales (Sydney, Australia) in the field of human gastrointestinal physiology, and undertook postdoctoral work in computational genetics and genomics, before obtaining an academic appointment at the John Curtin School of Medical Research, Australian National University, Canberra in 2007. He relocated to Singapore in 2011 to commence as a principal investigator of the Singapore Centre for Environmental Life Sciences Engineering (SCELSE), a Research Centre of Excellence co-hosted by the National University of Singapore and Nanyang Technological University, where he is the Head of the SCELSE Integrative Analysis Unit. At SCELSE he and his research group develop new methods for analysing the composition and function of microbiomes, with particular focus on the use of long read sequencing technology and multi-omics. Williams holds diverse research perspectives from this experience working in basic, clinical and environmental settings, including collaborations with two multinational companies and government agencies. He has published around 80 research papers, review articles and book chapters.

Damian O’Connell, Ph. D
Scientific Advisory Board, Member

Professor Damian O’Connell is Chief Executive Officer the Experimental Drug Development Centre at A*Star – the Agency for Science, Technology and Research based in Singapore. The Experimental Drug Development Centre is a national platform for drug and biomarker discovery as well as early clinical development.

Most recently Damian was Senior Vice President, Drug Discovery – Global Head of Clinical Sciences, Bayer Pharma AG, Berlin – Germany. Prof O’Connell previously held senior positions within Pfizer Research & Development, Parke Davis, Elan Pharmaceuticals and Neurex. Prof O’Connell has both MD & PhD degrees from the National University of Ireland, has been a Medical Faculty member of the University of Virginia Health Sciences Center as well as a member of the Clinical Pharmacology & Therapeutics Department at the University College Cork, Ireland where he was a Professor of Clinical Research. He started his career in the Industry in 1998.

Prof O’Connell is an Adjunct Professor at University College Cork, Ireland; Member Expert Advisory Panel, Singapore Translational Cancer Consortium;  Member Advisory Board Investigational Medicine Unit SingHealth, Singapore; Board Member INFANT Research Centre, Cork Ireland; Member Scientific Advisory Board, BluMaiden Biosciences, Singapore; Member of the Faculty of Pharmaceutical Medicine; Fellow of The Royal Society of Medicine; Fellow of The Royal Academy of Medicine (Ireland); Member of the British Pharmacological Society; Member of the Drug Safety Executive Council (DSEC); Member American Society for Clinical Pharmacology and Therapeutics; Member American College of Clinical Pharmacology.

Kim Lewis, Ph. D
Scientific Advisory Board, Member

Professor Kim Lewis – Professor Kim Lewis is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is a University Distinguished Professor and the Director of Antimicrobial Discovery Center at Northeastern University in Boston, Massachusetts. Formally he held faculty appointments at Massachusetts Institute of Technology, University of Maryland and Tufts University. A distinguished molecular microbiologist whose research career has focused on the mechanisms of antimicrobial resistance, Lewis is a Fellow of the American Association for the Advancement of Science and a Fellow of the American Academy of Microbiology.

Lewis’ research has resolved key problems underpinning the mechanisms by which bacteria can resist the action of antibiotics, discovered new classes of antibiotics and demonstrated the potential of finding antibiotic compounds in microbiomes. Lewis has a long-standing engagement with the biotech industry and pharma. At BluMaiden Biosciences, he is guiding the scientific team on approaches for discovering new therapeutic compounds from human microbiomes.

Nicholas Talley, Ph. D
Scientific Advisory Board, Member

Distinguished Laureate Professor Nicholas Talley AC is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is based at the University of Newcastle, Australia and held former appointments as Chair of the Department of Internal Medicine at Mayo Clinic in Jacksonville, Florida, a Professor of Medicine and Professor of Epidemiology at Mayo Clinic and Foundation Professor of Medicine at the University of Sydney, Nepean Hospital.

Professor Talley is considered one of the world’s leading authorities in diseases of the upper and lower gastrointestinal tract. Among other advances, his research has documented genetic determinants of irritable bowel syndrome (IBS), and the role of the immune system and gut microbiota in functional gastrointestinal disease. At BluMaiden Biosciences, he is guiding the scientific team as they develop pioneering solutions to human microbiome associated diseases.

Stephen Simpson, FRS, Ph. D
Scientific Advisory Board, Member

Professor Stephen Simpson, FRS is a Scientific Advisory Board member at BluMaiden Biosciences. Currently he is the Director of the Charles Perkin Centre at the University of Sydney, a Professor in the School of Life and Environmental Sciences at the University of Sydney, and Executive Director of Obesity Australia. Prior to his current appointments, Simpson was at the University of Oxford for over 20 years. In 2013 he was elected a Fellow of the Royal Society of London as “one of the world’s foremost entomologists and nutritional biologists”.

Simpson is a highly innovative thinker in nutritional science, having developed new measurement and modelling frameworks for studying nutritional intake behaviours in a range of organisms, including humans. This approach, termed nutritional ecology, draws on ecology and evolutionary theory to provide a new foundation for thinking about human nutrition. At BluMaiden Biosciences, he is guiding the scientific team in their attempts to build a platform for microbiome-enabled personalized nutrition.